Reply to M.S. Lesniak

Journal of Clinical Oncology

Volumn 29, Issue 22, 2011, Pages 3105-3106

  Mehta, Ankit I ^a   Persson, Oscar ^b   Herndon II, James E ^a   Archer, Gary E ^a   McLendon, Roger ^a   Heimberger, Amy B ^c   Mitchell, Duane A ^a   Bigner, Darell D ^a   Sampson, John H ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b LUND UNIVERSITY   (Sweden)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CANCER VACCINE; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; IRINOTECAN; TEMOZOLOMIDE;

CANCER IMMUNIZATION; EXTERNAL BEAM RADIOTHERAPY; GENE MUTATION; GLIOBLASTOMA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LETTER; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR BIOPSY; TUMOR RECURRENCE;

EID: 80051685308     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.35.0256     Document Type: Letter

References (8)

1. Lesniak MS: Immunotherapy for glioblastoma: The devil is in the details. J Clin Oncol 29:3105, 2011
2. Sampson JH, Heimberger AB, Archer GE, et al: Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma. J Clin Oncol 28:4722-4729, 2010
3. Heimberger AB, Hlatky R, Suki D, et al: Prognostic effect of epidermal growth factor receptor and EGFRvIII in glioblastoma multiforme patients. Clinical Cancer Res 11:1462-1466, 2005 (Pubitemid 40315227)
4. Yip S, Miao J, Cahill DP, et al: MSH6 Mutations arise in glioblastomas during temozolomide therapy and mediate temozolomide resistance. Clinical Cancer Res 15:4622-4629, 2009
5. Cancer Genome Atlas Research Network: Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455:1061-1068, 2008
6. Humphrey PA, Wong AJ, Vogelstein B, et al: Anti-synthetic peptide antibody reacting at the fusion junction of deletion-mutant epidermal growth factor receptors in human glioblastoma. Proc Natl Acad Sci U S A 87:4207-4211, 1990
7. Wikstrand CJ, Hale LP, Batra SK, et al: Monoclonal antibodies against EGFRvIII are tumor specific and react with breast and lung carcinomas and malignant gliomas. Cancer Res 55:3140-3148, 1995
8. Sampson JH, Aladape KD, Archer GE, et al: Greater chemotherapyinduced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma. Neuro-Oncology 13:324-333, 2011